Derek (More Plates More Dates) TRT Influence on Patient Demand

Who Is Derek, and Why Does His Channel Matter Clinically?

Derek runs More Plates More Dates (MPMD), a YouTube and podcast platform that publishes detailed, citation-heavy content on testosterone, hormone optimization, and pharmacology. His audience does not passively consume content; they print out episodes, screenshot bloodwork ranges, and bring both to their next clinic appointment.

The scale of this information transfer is not trivial. A 2021 analysis published in JAMA Internal Medicine found that health-related YouTube videos collectively reach more viewers per week than any single prime-time television broadcast, and that channels hosted by non-physicians are viewed 2.5 times more often than those hosted by medical professionals. [1] That dynamic describes the MPMD audience precisely.

From Gym Forum to Clinical Waiting Room

Derek's content began as bodybuilding harm reduction. Over roughly eight years, the scope expanded to cover testosterone cypionate dosing, estradiol management, fertility preservation on TRT, and now GLP-1 receptor agonists. The progression mirrors a broader cultural shift: men who once asked their primary care physicians only about fatigue now arrive with printed-out free testosterone and SHBG values and ask for specific protocols.

A 2023 survey in Translational Andrology and Urology documented that 62% of men presenting to urology clinics for low-testosterone evaluation had already researched their own management online before the appointment. [2] MPMD is consistently cited as a primary source in online community surveys on testosterone forums such as r/Testosterone and r/Hormones.

The Information Quality Question

Derek's content is notably more evidence-anchored than most fitness influencer output. He regularly cites pharmacokinetic studies, references the 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism, and reads primary literature on camera. That detail is both the appeal and the clinical complication: patients arrive with accurate pharmacology but incomplete clinical context.

The Endocrine Society guideline itself states: "We recommend against a general policy of offering testosterone therapy to all men with low testosterone concentrations." [3] That nuance rarely survives the translation from a 90-minute deep-dive video to a patient's self-diagnosis.

How MPMD Shapes Specific Patient Requests

Patients influenced by MPMD arrive with a recognizable request pattern. They typically want testosterone cypionate (not gel), twice-weekly injections (not weekly), a specific target for serum estradiol (often 20-30 pg/mL), and a plan for preserving fertility via hCG or enclomiphene. Each element reflects something Derek has discussed in detail.

Testosterone Cypionate and Injection Frequency

Derek has produced multiple videos arguing that twice-weekly injections of testosterone cypionate produce more stable serum levels than once-weekly dosing. The pharmacokinetic logic is sound. Testosterone cypionate has a half-life of approximately 8 days, meaning twice-weekly dosing reduces peak-to-trough fluctuation. A 2020 modeling study in The Journal of Clinical Pharmacology confirmed that shorter injection intervals reduce estradiol excursion and may lower hematocrit variability. [4]

Patients come in citing this directly. The clinical implication is that the request is often medically defensible, but the dose they bring with them (commonly 200 mg/week self-researched from forum data) may exceed what an individualized assessment supports. The Endocrine Society recommends targeting a mid-normal range of roughly 400-700 ng/dL, not maximizing to the top of the reference interval. [3]

Estradiol Management and Aromatase Inhibitor Use

Derek's position on estradiol is more nuanced than most online sources, but it still generates clinical pressure. He recommends monitoring estradiol with a sensitive assay (LC-MS/MS, also called the "sensitive" or "Equilibrium Dialysis" estradiol test) rather than the standard immunoassay. That recommendation aligns with published guidance; a 2013 paper in JAMA demonstrated that LC-MS/MS estradiol measurement is significantly more accurate in men than immunoassay. [5]

Where the clinical friction arises is around anastrozole. Derek has discussed anastrozole use at 0.25-0.5 mg twice weekly to control estradiol, a protocol that many MPMD-informed patients request. Suppressing estradiol too aggressively causes bone mineral density loss, lipid deterioration, and sexual dysfunction. A study in The New England Journal of Medicine showed that estradiol suppression with aromatase inhibitors in men significantly reduced bone density within 16 weeks. [6] Prescribing physicians must push back against reflex AI use when estradiol is at physiologic levels.

hCG and Fertility Preservation

MPMD content has done more to spread awareness of hCG co-administration for testicular volume and fertility preservation than most academic endocrinology outreach. Derek consistently explains that exogenous testosterone suppresses LH and FSH, and that hCG (human chorionic gonadotropin) mimics LH to maintain intratesticular testosterone and spermatogenesis.

That biology is correct. The American Urological Association's 2018 guideline on male infertility confirms that hCG-based protocols can preserve fertility in men on testosterone therapy. [7] What MPMD patients sometimes miss is the cost and supply-chain complexity of compounded hCG, the shift to Pregnyl (brand) after the FDA discontinued certain compounded formulations, and the need for serial semen analysis to verify efficacy.

Enclomiphene as a TRT Alternative

One of Derek's more clinically influential contributions is his detailed coverage of enclomiphene citrate. Unlike clomiphene (a racemic mixture), enclomiphene is the trans-isomer alone and carries less of the estrogenic activity associated with the zuclomiphene isomer. Derek has discussed enclomiphene as a way to raise endogenous testosterone while preserving the hypothalamic-pituitary-gonadal axis.

The clinical evidence supports cautious optimism. A Phase 3 trial published in Fertility and Sterility showed enclomiphene at 12.5-25 mg/day raised total testosterone to normal range in secondary hypogonadism while maintaining sperm counts, unlike exogenous testosterone. [8] Enclomiphene is not FDA-approved as of early 2025, meaning physicians prescribing it do so off-label, a fact that MPMD-informed patients sometimes underestimate.

The Telehealth Prescribing Pressure Problem

The combination of a large, educated audience and low-friction telehealth access creates a specific clinical challenge. Patients can research a protocol on MPMD, book a telehealth appointment with a hormone clinic, and receive a prescription within 48 hours, sometimes without a full metabolic panel, sleep apnea screening, or digital rectal examination discussion.

What Guidelines Actually Require Before Starting TRT

The 2018 Endocrine Society Clinical Practice Guideline specifies a clear diagnostic pathway. Total testosterone below 300 ng/dL on two separate morning samples, plus at least one symptom of hypogonadism. Screening should include CBC (to assess baseline hematocrit), PSA if age warrants it, and LH/FSH to distinguish primary from secondary hypogonadism. [3]

Obstructive sleep apnea is an important pre-treatment consideration. Testosterone therapy may worsen OSA, and a 2016 meta-analysis in CHEST found that TRT increased the severity of sleep-disordered breathing in susceptible men. [9] A telehealth intake that skips sleep history misses a real safety signal.

The "Optimization" vs. Treatment Distinction

Derek's content straddles a line that clinical medicine has not fully resolved: the difference between treating symptomatic hypogonadism (a defined condition) and "optimizing" testosterone in men who test within the normal range but feel suboptimal. He is generally transparent that he is discussing optimization, not necessarily medical treatment. That distinction frequently dissolves by the time the patient reaches the clinic.

A 2019 review in Annals of Internal Medicine found no consistent improvement in quality of life, sexual function, or energy in men with low-normal testosterone (300-400 ng/dL) treated with TRT vs. Placebo over 12 months. [10] That evidence does not mean no individual benefits, but it does mean physicians should not simply ratify a patient's self-diagnosis.

A Clinical Decision Framework for MPMD-Informed Patients

When a patient arrives citing MPMD protocols, the visit can be structured in three distinct phases.

Phase 1: Validate the research, not the prescription. Acknowledge that the patient has done genuine pharmacological homework. Review their cited sources. This preserves rapport and surfaces what they actually understand vs. What they have misread.

Phase 2: Run the full diagnostic before discussing protocol. Order total testosterone (morning draw, twice if first is below 400 ng/dL), free testosterone via equilibrium dialysis, SHBG, LH, FSH, estradiol (sensitive assay), CBC, comprehensive metabolic panel, PSA (age-appropriate), and a sleep disorder screening questionnaire. Protocol discussion waits until these return.

Phase 3: Individualize against their specific values. A patient with total testosterone of 280 ng/dL, LH of 1.2 mIU/mL, and active fertility goals is a candidate for enclomiphene, not testosterone cypionate. A patient with total testosterone of 410 ng/dL and fatigue needs a thyroid panel and sleep study before any hormone prescription.

What Derek Gets Right, and Where Clinical Caution Is Needed

Fairness requires both. MPMD content has meaningfully raised the baseline pharmacological literacy of men seeking hormonal care. That is not nothing. Patients who understand the difference between total and free testosterone, who know what SHBG does, and who ask for LC-MS/MS estradiol testing are easier to work with and more likely to adhere to monitoring schedules.

Accurate Content With Real Clinical Value

Derek's coverage of polycythemia risk on TRT is accurate and often exceeds what patients hear from busy primary care physicians. He correctly advises that hematocrit above 54% warrants dose reduction or therapeutic phlebotomy, which aligns with the Endocrine Society guideline threshold. [3] His coverage of cardiovascular risk is also more balanced than critics suggest; he consistently notes that TRT's cardiovascular safety data has been mixed and that the TRAVERSE trial (N=5,198) was the first large RCT to show non-inferiority to placebo for major adverse cardiovascular events in men with or at high risk for cardiovascular disease. [11]

Where the Content Oversteps

The primary gap is individualization. Derek presents population-level pharmacokinetics as if they translate directly to every listener. A viewer who metabolizes testosterone rapidly due to high SHBG will not hit the same serum levels as one with low SHBG at the same dose. A viewer with hemochromatosis or sleep apnea faces risks that a YouTube protocol simply cannot screen for.

Derek's peptide content (BPC-157, TB-500, CJC-1295, Ipamorelin) also extends well beyond available RCT evidence. Human data for most of these compounds is limited to small pilot studies or case reports. Patients requesting these compounds at telehealth visits often cite MPMD as primary evidence, but the compounds have no FDA approval and the evidence base does not support routine clinical use. [12]

The Broader Effect on TRT Prescribing Volumes

MPMD's influence is one factor in a measurable trend. Between 2010 and 2023, testosterone prescriptions in the United States rose sharply, then partially contracted after the FDA added cardiovascular warning labels in 2015, then rose again as telehealth expanded during and after 2020. A 2022 study in JAMA Internal Medicine found that testosterone prescription rates among men aged 18-45 increased by 45% between 2016 and 2021, with the steepest growth in the 25-34 age bracket. [13]

Not all of this is attributable to MPMD. Direct-to-consumer TRT telehealth companies, podcasts, and social media broadly contributed. But MPMD's audience skews precisely toward men 25-44, the segment showing the fastest prescribing growth. Correlation is not causation, but the demographic overlap is exact.

Physician Responses in Practice

Some hormone physicians report that MPMD-informed patients are their best patients: engaged, adherent, likely to monitor labs, and motivated to understand their results. Others report the opposite: patients who resist deviating from a protocol they found online, refuse dose reductions when hematocrit rises, or self-source compounded testosterone outside the clinic.

The American Urological Association's 2022 testosterone deficiency guideline notes that clinician-patient shared decision-making must account for patient preferences and information sources, without endorsing unsupervised self-dosing. [14] That balance is exactly what the MPMD-influenced consultation tests.

Clinical Takeaways for Physicians Seeing MPMD-Informed Patients

Patients who cite MPMD are a specific clinical phenotype. They have done meaningful research, they have specific expectations, and they are often correct about the pharmacology while being wrong about whether it applies to their individual case.

The practical response is not to dismiss the information source. Attempting to discredit a patient's research without engaging its substance damages rapport and reduces adherence. The more effective approach is to use the patient's existing framework as a starting point, then layer in the individualization that no YouTube channel can provide.

Run complete diagnostics first. Discuss protocol only after results return. If total testosterone is below 300 ng/dL on two draws with confirmed symptoms, initiate therapy per guideline. If total testosterone is 350-450 ng/dL and the patient is symptomatic, investigate thyroid, sleep, and metabolic causes before attributing symptoms to testosterone.

A patient whose SHBG is 68 nmol/L (producing a low free testosterone despite adequate total testosterone) may benefit from treatment, but the treatment target and dose calculation differ materially from a patient with SHBG of 22 nmol/L. That calculation requires a physician. MPMD says so, too. The TRAVERSE trial enrolled men with confirmed hypogonadism; baseline total testosterone in enrolled subjects was below 300 ng/dL, a threshold the study's authors called the appropriate lower bound for treatment decisions. [11]